Search

everythinglearnresearchcommunity

for

Search:↓

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

AHK and GHK are discussed for hair growth in the crown area, with questions about side effects and safety after microneedling. Users share experiences and concerns about these treatments.

The conversation is about trying PTD-DBM for hair loss treatment. Users are curious about its effectiveness and results.

The user is using testosterone and finasteride to prevent hair loss and is considering adding Primobolan or Masteron, which are DHT-derivatives. They are seeking advice on their genetic risk for male pattern baldness and whether they can safely use these compounds without significant hair loss.

A user reported significant hair thickening and new baby hairs on the hairline after 11 months of using 1mg finasteride every other day and microneedling once a week. They experienced no shedding, and finasteride stopped all hair loss within 24 hours of the first pill.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

A user who shared progress pictures of their scalp using a microscope camera, demonstrating the difference between healthy and miniaturized hair. Various explanations for the cause of this were discussed, such as DHT build-up in scalp sebum causing an autoimmune response leading to inflammation and eventual hair loss, with some suggesting a do-it-yourself treatment involving adding ascorbic acid powder to shampoo.

Keratin microspheres may offer additional mechanisms to combat hair loss compared to minoxidil. The process to create these microspheres is relatively simple and can be done at home with basic equipment.

A Spanish dermatologist suggests sulforaphane for androgenetic alopecia (AGA) due to its potential to remove DHT metabolites, though high dosages are needed. A topical formulation might be possible.

The conversation discusses how different factors can stimulate type 1 and type 2 isoforms of 5-alpha reductase, which are enzymes linked to hair loss. Specific treatments mentioned include oral Dutasteride and topical Finasteride.

A user shared their year-long hair loss treatment using minoxidil, microneedling, and scalp massages, reporting moderate hair growth and stabilization. They suggest starting early with less harmful methods and consider adding finasteride or dutasteride if needed.

A 20-year-old woman with androgenetic alopecia feels depressed about her hair loss, despite using topical minoxidil, spironolactone, and saw palmetto. Suggestions include trying oral minoxidil, higher doses of finasteride or dutasteride, and checking for vitamin deficiencies and heavy metal exposure.

The conversation discusses the effectiveness of a hair loss treatment called CB (Breezula) in comparison to Pyrilutamide, and its potential when combined with Finasteride. There is uncertainty about when or if phase 3 trials for Breezula will begin.

Finasteride and dutasteride are discussed for hair loss, with concerns about their effects on neurosteroids and potential side effects like depression. Alternatives like topical estrogen and lifestyle changes are considered, with varying opinions on mental health and hair regrowth.

The user experienced side effects from spironolactone and is seeking alternatives for androgenetic alopecia (AGA), considering saw palmetto but unsure of its effectiveness. They are also exploring the possibility of using topical spironolactone, despite availability challenges.

Han Bio claims success in hair multiplication using dermal papilla cells. Treatments discussed include Minoxidil, finasteride, and RU58841.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

Breezula's phase 3 enrollment for hair loss treatment is complete, but results have not been published, causing skepticism about its progress. Some users express doubt about its future, suggesting it may be reserved for exclusive use.

The user experienced new hair growth after switching from oral finasteride to topical RU58841 with minoxidil and undergoing stem cell therapy. They noticed new hairs at the hairline and temples, but are unsure which treatment is responsible.

User seeks availability of Breezula and its delayed trials. Asks for success with similar topical antiandrogens like fluridil.

A user shared their 4-month progress using 2.5mg minoxidil, 1mg finasteride, and 10mg biotin, noting slight testicular discomfort initially but no significant hairline changes yet. Another user reported similar treatment results, with hair darkening at the scalp center and small temple hairs.

A user is considering adding PRP and mesotherapy to their hair loss treatment and is deciding between two options: Promoitalia, which contains Phosphatidic acid, Riboflavin, and Superoxide dismutase, and the more expensive Melsmon, a human placenta derivative. They seek advice on which option to choose based on effectiveness and scientific backing.

The conversation is about a hair loss product that claims to use stem cells and ingredients like Capixyl, Redensyl, and Baicapil, with the user asking if anyone has looked into it. No specific treatments were discussed.

Han Bio plans to start clinical trials for a new hair multiplication technology this year, which could significantly reduce the cost and time of hair transplantation. The technology uses a single hair strand to cultivate enough cells for 30,000 hair strands.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

Researching and developing an effective local antagonist to block the androgen receptors for hair loss, as opposed to using DHT synthesis inhibitors that lower serum DHT levels. Several treatments such as CosmeRNA and Pyrilutamide are currently in development or undergoing trials.

The user reported noticeable hair improvement over four months using 1 mg of finasteride and weekly microneedling. Progress photos from October 2024 to January 2025 show positive changes.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

The conversation discusses androgenic alopecia (AGA) and its treatments, focusing on finasteride, minoxidil, and ketoconazole shampoo. Finasteride is recommended as essential for preventing further hair loss.